BPCP — Biopharma Credit Cashflow Statement
0.000.00%
- £724.38m
- £720.16m
- $150.03m
- 80
- 81
- 71
- 93
Annual cashflow statement for Biopharma Credit, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Changes in Working Capital | 58.1 | 96.4 | 184 | 123 | 112 |
Other Operating Cash Flow | |||||
Cash from Operating Activities | 58.1 | 96.4 | 184 | 123 | 112 |
Other Investing Cash Flow Items | -47.5 | -94.8 | 48.2 | -1.66 | 39.1 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -47.5 | -94.8 | 48.2 | -1.66 | 39.1 |
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | -114 | -100 | -207 | -107 | -280 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -103 | -98.6 | 25.8 | 14.5 | -129 |